Dr Giedrius Gasiūnas, CEO and Co-Founder of Caszyme, describes the company’s research into engineered CRISPR-Cas12l nuclease Asp2Cas12l M82, a potential new tool for genome editing and the development of gene therapies. CRISPR has become one of the most widely used tools for gene editing across research and… Read More
Dr Shi-qi An and Dr Naira Movsisyan of Novogene Europe consider why multiomics studies should follow biological responses over time, and how carefully chosen sampling points can distinguish initiating mechanisms from adaptation, compensation and the molecular signatures left by surviving cells. In drug discovery, a compound is often assessed by… Read More
The Edinburgh Genome Foundry (EGF), one of the world’s leading bio-foundries, is collaborating with The Advanced Research and Invention Agency (ARIA) to accelerate biological research and unlock new discoveries that benefit everyone. The three-year programme will provide ARIA with access to and expansion of EGF’s automated laboratory… Read More
University of Queensland (UQ) scientists will accelerate research into cures for life-threatening genetic diseases from a Brisbane-based node of the new Medical Research Council Centre of Research Excellence for Mitochondrial Genome Therapeutics. Associate Professor Seth Cheetham from UQ’s Australian Institute for Bioengineering and Nanotechnology and Chief Investigator of… Read More
The UK’s Medical Research Council has invested £50 ($67.3) million into the study of mitochondrial diseases for improved treatments. The new MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics brings together leading experts from across disciplines to define how mutations in mitochondrial DNA (mtDNA) cause disease… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer drug demonstrated it could reduce tumours by as much as… Read More
News round-up for 1 June – 5 June by Bruno Quinney, Content Team at DDW. This week, a cancer drug has demonstrated it could reduce tumours by as much as 55%. Elsewhere, AI has been a recurrent theme in both clinical trials and drug development. The top stories:… Read More
Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, a large international clinical trial led by University College London (UCL) has found. The OPTIMA trial (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) followed more than 4,400 patients… Read More
Scientists have created the most comprehensive map to date of the genetic mutations that fuel cancer — opening the door to extending precision treatments to thousands more patients and offering clues as to why bowel cancer rates are rising in younger people. The landmark… Read More
Advances in artificial intelligence and synthetic biology are driving a new frontier in genomic research. Megan Thomas explores what the future of genomics will look like. New technologies for the future In a Eureka! podcast interview with McKinsey, Howard Jacob, Vice President of Genomics Research… Read More
Megan Thomas provides overview of the global market for genomics, covering its rapid reshaping of drug discovery and development to offer faster, more precise, and cost-effective pathways to new therapies while driving global collaboration and innovation. Past to present As far back as 2000, academic experts… Read More
A collaboration between ARC Innovation at Sheba Medical Center, Icahn School of Medicine at Mount Sinai and NVIDIA will use the power of artificial intelligence (AI) in a bid to better understand the unexplored regions of the genome. The three-year collaboration will see the groups work together to… Read More
Dr Jeremy Wilkinson, Microbial Genomics Lead, PacBio, explores how genomics are enabling higher-resolution microbiome profiling and highlights four therapeutic areas where this new… Read More
New gene therapy trial results have shown dramatic and sustained improvements in hearing and speech perception in children with profound genetic hearing loss. The updated data for Regeneron Pharmaceuticals’ investigational gene therapy DB-OTO for profound genetic hearing loss due to variants of the otoferlin (OTOF) gene were… Read More
Genomic and spatial technologies are helping to bring greater insights into cancer and diseases such as long Covid, writes Jack DiGiovanna, Chief Science Officer at Velsera. Emerging genomic and spatial technologies are transforming research on complex diseases like cancer and long Covid. These advancements offer unprecedented precision in diagnostics and… Read More
A collaborative project led by the Max-Planck Institute of Molecular Plant Physiology (MPI-MP), Germany, aims to develop synthetic chloroplast genomes. Enzymatic DNA synthesis company Camena Bioscience and whole genome writing specialists Constructive Bio are the latest companies to join the project. Until now, constructing synthetic… Read More
